Loading the session
Loading the session
Loading instrument
$18.71
−1.47%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:37 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 close of $18.99 was 1.3% below its 50-day average ($19.24) and 1.6% above its 200-day average ($18.68). It has closed above the 200-day for 1 session, since 4 Nov 2026. The 50-day average crossed above the 200-day on 9 Oct 2026, 18 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
22.3M shares were sold short at the 15 Oct 2026 settlement, 21.1% of the 105.6M shares outstanding; covering them would take 7.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +9.7% (SPY −1.6%, XLV +13.5%). 3 months: +19.2% (SPY −0.4%, XLV +15.5%). 1 year: +17.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SRPT, SPY and XLV · as of 4 Nov 2026
Closed at $18.99 on 4 Nov 2026: 23.1% below the 52-week high of $24.68 (26 Jan 2026) and 29.4% above the low of $14.68 (11 Jun 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
July 18, 2025
−35.94%June 16, 2025
−42.12%October 31, 2023
−37.47%